Credits: Canva
Before we get into how to correctly perform CPR, it is important to know what CPR is?
CPR stands for Cardiopulmonary Resuscitation, it is a crucial life-saving technique, which is used when someone stops breathing or their heart stops beating. This required acting quickly as it can double or even triple the person’s chances of survival.
This step-by-step guide lays down guidelines to perform CPR on people across ages including children, adults and the elderly.
The question is when would you know that it is the right time to perform CPR? For adults, if they are not responsive or are not breathing, it might be the right time to perform CPR. Same is the case for everyone else. However, you must avoid performing CPR if the person is just unconscious but is breathing. One must never perform CPR on a person who is conscious and breathing. It is important to also allow them the space once they gain back their conscious so they can breathe and gasp as much air as needed.
Check your surroundings for dangers, is there traffic? Is there a chance of fire or objects falling? If yes, try to reach and take the person to a safe place.
Place the person on their back on a firm surface. Now, tilt the person's head back slightly and lift the chin up to open the airway. It is important to do so to allow the air in. Look inside their mouth for any obstruction before performing CPR. If you see any object, carefully remove it.
Listen for breathing sounds for no more than 10 seconds, if there are no beats, then perform CPR.
Place the heel of one hand on the center of the chest, slightly below the nipple line. Place your other hand on top and interlock your fingers.
Keep your elbows straight and push hard and fast—around 2 inches deep—at a rate of 100–120 compressions per minute.
Allow the chest to rise fully between compressions.
After 30 compressions, tilt their head back, lift the chin, pinch their nose, and seal your mouth over theirs.
Give two rescue breaths, each lasting about 1 second, watching for chest rise.
If the chest doesn’t rise, reposition the head and try again.
Continue alternating 30 chest compressions and 2 rescue breaths until the person starts breathing or professional help arrives.
For children, tap the shoulder; for infants, gently flick the sole of the foot to check for a response.
If unresponsive and alone, provide 2 minutes of CPR before seeking emergency help.
For children: Use one hand for chest compressions, pressing down 2 inches (or one-third of the chest’s depth).
For infants: Use two fingers in the center of the chest, pressing down 1.5 inches.
For children, pinch the nose and cover their mouth with yours to give two breaths.
For infants, cover both the nose and mouth with your mouth and deliver gentle breaths.
Repeat cycles of 30 compressions and 2 breaths until the child or infant begins breathing or professional help arrives.
Use CPR for emergencies like cardiac arrest, drowning, choking, or trauma.
Always ensure the person is unresponsive and not breathing before starting CPR.
Be prepared to adjust techniques for infants, children, and adults based on their size.
Note: this is only for emergency circumstance. If there is a healthcare or a medical professional next to you, it is always advisable to seek for their help.
(Credit-Canva)
A sixth person has died from the Legionnaires’ disease outbreak in Central Harlem, according to New York City health officials. The city is currently investigating the outbreak that began in late July, which has now affected over 100 people.
As of Thursday, 111 people have been diagnosed with the disease. The recent death was of a person who passed away outside of New York City earlier this month, but their death was only recently linked to the outbreak. There are currently seven people hospitalized.
The city has identified and cleaned 12 cooling towers on 10 buildings, including a city hospital and a clinic, where the bacteria were found. These cooling towers, which use water to cool buildings, are believed to be the source of the outbreak.
Legionnaires' disease is a severe type of pneumonia caused by a bacteria called Legionella. This bacteria thrives in warm water and can spread through a building’s water system. People usually show flu-like symptoms, such as a cough, fever, and muscle aches, within two days to two weeks after they are exposed to the bacteria.
Health officials are advising anyone who lives or works in the Central Harlem area to contact a doctor if they experience these symptoms.
The disease often starts like a mild flu. For the first couple of days, you might have muscle aches, body aches, and headaches. But after this initial phase, the symptoms get much worse.
You might develop a high fever of 100.4°F or higher, along with chills and extreme tiredness. About half of the people who get sick also experience confusion or delirium. Other symptoms include an upset stomach, with nausea, vomiting, and diarrhea. Since the bacteria attack the lungs, you will likely have a persistent cough that can start out dry but may later produce mucus or even blood. You may also feel short of breath and have chest pain.
The time it takes for you to get sick after being exposed to the Legionella bacteria is called the incubation period. It can be as short as two days or as long as 19 days. Most people, however, start feeling sick around six to seven days after they've been exposed. This is the time the bacteria need to grow inside your body before they cause noticeable symptoms.
Pontiac fever is a milder version of the same infection. Its incubation period is much shorter, usually just one to two days. The symptoms are less severe and include a flu-like sickness with muscle pain, headaches, and a fever. Unlike Legionnaires' disease, Pontiac fever usually goes away on its own without needing a lot of medical care. Because it is so mild, doctors sometimes don't even realize it's Pontiac fever.
Doctors can figure out if you have Legionnaires’ disease using a few different tests. They will often check your blood and urine or look for the bacteria in a sample of your sputum (the mucus you cough up). They may also take a chest X-ray, but this can be tricky because the results look like other types of pneumonia.
The best way to get a clear diagnosis is through lab tests that can directly identify the bacteria. It's also a clue that you have it if your illness doesn't get better with common antibiotics like penicillin. Without treatment, the illness can get much worse and may lead to serious problems like kidney failure, respiratory failure, and even death.
Credits: iStock
Stem cell transplantation has long stood as one of medicine’s most powerful tools, offering hope to patients with genetic disorders, immune deficiencies, and blood cancers. But it comes at a staggering cost: before healthy donor cells can take root, patients typically undergo toxic chemotherapy or radiation to destroy their own diseased bone marrow. The side effects can be devastating — infertility, organ damage, secondary cancers, and sometimes death.
Now, researchers at Stanford Medicine have shown it doesn’t always have to be this way. A Phase 1 clinical trial published in Nature Medicine has demonstrated that an antibody-based treatment can safely prepare patients for a stem cell transplant without using busulfan chemotherapy or radiation. For children with Fanconi anemia, a rare genetic disorder that makes conventional transplants particularly dangerous, this represents nothing short of a medical breakthrough.
Traditionally, transplants hinge on “conditioning” — a process to clear out faulty bone marrow so donor cells can settle in. Until now, that has required high doses of chemotherapy or radiation, treatments that damage DNA and leave lifelong scars.
The Stanford team instead used briquilimab, an antibody that targets CD117, a protein on blood-forming stem cells. By binding to CD117, the antibody wipes out diseased stem cells without blasting the rest of the body with toxins.
“We were able to treat these really fragile patients with a new, innovative regimen that allowed us to reduce the toxicity of the stem cell transplant protocol,” said Dr. Agnieszka Czechowicz, MD, PhD, assistant professor of pediatrics and co-senior author of the study.
For Fanconi anemia patients, who are hypersensitive to DNA damage, eliminating busulfan and radiation could be life-saving.
The Phase 1 trial enrolled three children with Fanconi anemia, each younger than 10 years old. Instead of the usual conditioning, they received a single infusion of briquilimab 12 days before transplant, followed by low-intensity immune suppression but no chemotherapy or radiation.
The donor bone marrow came from their parents — genetically half-matched but specially prepared. Researchers enriched it with CD34+ stem cells while removing alpha/beta T-cells, immune cells known to trigger graft-versus-host disease.
The results stunned the team. Within two weeks, the donor stem cells had taken hold. By 30 days, healthy blood production was underway. Two years later, all three children have nearly 100% donor cells in their bone marrow, far exceeding the trial’s goal of just 1%.
“No one experienced graft rejection, and the outcomes were better than we had dared to expect,” Czechowicz said.
This success is decades in the making. Stanford’s Dr. Irving Weissman first studied CD117 antibodies in mice nearly 20 years ago. Step by step, researchers refined the science until a clinical-grade antibody was ready for human trials.
The first child to benefit was 11-year-old Ryder Baker from Texas. Before his transplant, Ryder was exhausted by his illness. “He was so tired, he didn’t have stamina,” recalled his mother, Andrea Reiley. Today, Ryder is thriving — playing soccer, enjoying pickleball, and even earning the title of “Up and Coming Player” at school.
Reiley says her son takes pride in being a pioneer. “I have conversations with him about how his experience is helping doctors take better care of other kids. I think he takes a lot of pride in that too.”
Fanconi anemia is a genetic disorder of DNA repair. The body’s stem cells can’t fix everyday DNA damage, leading to progressive bone marrow failure. Children often develop fatigue, infections, and bruising before age 12. Without a transplant, they face life-threatening complications.
But because their DNA-repair machinery is so faulty, standard chemo or radiation is especially harmful. “Right now, nearly all of these patients get secondary cancers by the time they’re 40,” Czechowicz noted.
The antibody-based method offers a way out of this deadly paradox, a path to transplant without the genotoxic conditioning that accelerates cancer.
Another innovation lies in how donor cells are prepared. For decades, 35–40% of patients never received transplants simply because they lacked a perfectly matched donor. Using half-matched donors like parents — while carefully engineering the graft to reduce complications — expands the donor pool dramatically.
“We are expanding the donors for stem cell transplantation in a major way, so every patient who needs a transplant can get one,” explained Dr. Rajni Agarwal, MD, co-first author and professor of pediatric stem cell transplantation.
This has profound implications not only for Fanconi anemia, but also for other inherited blood disorders like Diamond-Blackfan anemia and even some immune deficiencies.
Stem cell transplants are most commonly used in blood cancers like leukemia and lymphoma. While cancer patients may still require some chemotherapy or radiation to clear malignant cells, researchers believe antibody-based conditioning could benefit those too frail for full-dose regimens — including elderly patients.
Another Stanford team is already exploring whether briquilimab could be used in this vulnerable population.
“We may finally have a way to treat these patients with less intensity, so it’s possible for them to get a transplant,” Agarwal said.
Even with this breakthrough, transplants remain grueling. Ryder and the other children spent over a month in the hospital, battling side effects like exhaustion, nausea, and hair loss. And there is the broader issue of drug availability. Briquilimab is still in clinical trials, and scaling up access will take time.
Still, for families who once faced impossible odds, the difference is profound. “When I counsel families, their eyes start to shine as they think, ‘OK, we can avoid the radiation and chemo toxicity’,” Agarwal said.
The Stanford team is now running a Phase 2 trial in more children with Fanconi anemia, and they plan to extend the approach to other disorders. Longer-term, researchers hope antibody-based regimens can be combined with gene editing therapies — replacing faulty genes while avoiding the toxic prep work.
Czechowicz believes this is just the beginning, “We were optimistic, but we’ve been surprised by how well it’s worked. This could redefine how we think about stem cell transplantation.”
Credits: Canva
Maryland has reported its first human case of West Nile virus (WNV) of 2025, according to the state’s Department of Health. The patient was an adult resident of central Maryland, and officials said Friday that the patient was recovering from the disease. This news highlights the ongoing caution needed as mosquito season picks up across the United States.
West Nile virus is transmitted primarily through bites from infected mosquitoes that have previously fed on birds carrying the virus. While rare, the disease can occasionally spread through other avenues, but mosquito transmission remains the most common pathway.
The majority of individuals who contract WNV have no symptoms, but in certain instances, particularly in patients with underlying disease, the virus can result in serious disease. The Centers for Disease Control and Prevention (CDC) states that common symptoms develop 2–6 days following an infectious mosquito bite and might include high fever, headache, stiff neck, confusion, tremor, convulsions, loss of vision, weakness of muscles, numbness, or paralysis.
Health authorities note that there is no antiviral treatment available for West Nile virus. The vast majority of patients recover completely, although neuroinvasive infections—where the virus invades the central nervous system—are intensive to treat and tend to have more extended recovery times.
Kansas public health officials are tracking six WNV cases this year thus far. Five of these cases have been designated as neuroinvasive, illustrating the severity of the virus. There were three cases reported in north-central Kansas, and three in south-central Kansas. Non-neuroinvasive cases usually exhibit milder, flu-like illnesses, while neuroinvasive cases can include inflammation of the brain or the surrounding tissues, confusion, paralysis, and loss of vision, said Jill Bronaugh, a KDHE spokesperson.
Though numbers fall short of last year's figures—64 cases and four fatalities—officials caution that mosquito activity will peak in late summer, raising the potential for more cases. To monitor developments, KDHE hosts a weekly-updated West Nile virus dashboard for the surveillance season, which runs July to September.
The CDC reports that WNV activity in the United States normally begins in mid-August and lasts until early September. Around 2,000 individuals are diagnosed with the virus every year, although cases of mild or asymptomatic infections tend to be under-reported. The health authorities advise residents to use preventive strategies, such as using insect repellents, long sleeves, and pants while outdoors, and removing standing water near homes, which is a mosquito breeding site.
"Prevention is the key," states Dr. Emily Johnson, an infectious disease expert. "Because there's no treatment for West Nile, avoiding exposure to mosquitoes through bites is still the best way to stay safe and your family."
In addition to prevention on a case-by-case basis, scientists are looking at new approaches to fighting mosquito-borne illnesses, such as WNV. Anita Saraf, director of the University of Kansas's Mass Spectrometry & Analytical Proteomics Laboratory, is researching mosquito saliva to determine how viruses are transferred and to discover possible therapy targets.
Saliva collection from mosquitoes is technically difficult because they only produce minuscule amounts. USDA Agricultural Research Service collaborators stimulate the mosquitoes to produce saliva, which is analyzed using sophisticated mass spectrometry procedures by researchers. Saraf's research is being done on the proteome—the entire complement of proteins—in mosquito saliva and how it gives clues about how viruses such as West Nile, dengue, yellow fever, and Japanese encephalitis go about controlling the mosquito host and then impact humans.
Her work utilizes shotgun proteomics in tandem with nanoscale liquid chromatography and tandem mass spectrometry (nLC-MS), methods sensitive enough to examine nano-gram levels of protein. "Without the sensitivity, we would require much larger protein samples," Saraf says. "Our strategy permits us to explore these viruses at the molecular level, which might guide future vaccine or therapeutic design."
Health officials continue to emphasize simple prevention measures as the best defense against WNV. These are:
By doing these, residents will be able to drastically lower their chances of infection, particularly when it comes to the active mosquito season.
While Kansas and Maryland are tracking WNV cases at present, the threat is spread throughout the U.S. and the world. The CDC reports that West Nile virus is a continued public health issue every summer, especially in areas with high mosquito populations. Rare neuroinvasive cases show the virus's ability to cause significant damage to the nervous system, highlighting awareness and prevention.
The research undertaken currently at the University of Kansas demonstrates the innovative work towards understanding mosquito-borne viruses at a molecular level.
© 2024 Bennett, Coleman & Company Limited